Found 1739 clinical trials
A Study of SGN-B6A in Advanced Solid Tumors
This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether …
- 0 views
- 19 Feb, 2024
- 3 locations
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with neurofibromatosis type 2 (NF2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow …
- 0 views
- 19 Feb, 2024
- 2 locations
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
The investigators propose a phase II randomized-controlled study on using durvalumab in combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant durvalumab, compared to induction chemotherapy followed by concurrent chemoradiation for previously untreated locoregionally advanced stage III to IVA NPC. In parallel, the investigators will also perform collateral tumor …
- 0 views
- 19 Feb, 2024
- 1 location
Cancer Genome Atlas of China:Lung Cancer
Based on 2500 lung cancer tumor tissue samples from about 40 clinical centers in China, the molecular typing of lung cancer in China will be figured out by high throughput sequencing, which will provide the basis for the follow-up research and development of new drugs as well as the guidance …
- 0 views
- 19 Feb, 2024
- 31 locations
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC
In this observational study, we evaluated the difference of gene mutation and immune microenvironment and therapeutic effect in primary NSCLC.
- 0 views
- 19 Feb, 2024
- 1 location
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e.
- 0 views
- 19 Feb, 2024
- 1 location
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC. The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.
- 0 views
- 19 Feb, 2024
- 5 locations
Development and Analysis of a Stool Bank for Cancer Patients
This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are …
- 0 views
- 19 Feb, 2024
- 2 locations
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
Here we conducted this real world study to see whether neoadjuvant immunotherapy would bring MPR and survival benefits in NSCLC, for example, single agent immunotherapy or immunotherapy combination with chemotherapy. Furthermore biomarker analysis would be also performed to achieve personalized neoadjuvant immunotherapy.
- 0 views
- 19 Feb, 2024
- 1 location